Increased expression of CD44s in conventional renal cell carcinomas with renal vein or vena cava thrombosis: A retrospective evaluation of the expression of CD44s by immunohistochemical analysis in conventional RCC patients and in conventional RCC patients with renal vein or vena cava thrombosis

Urologia Internationalis

Volumn 81, Issue 4, 2008, Pages 452-455

  Altinel, Mert ^a   Arpali, Emre ^a   Turhan, Nesrin ^a   Gonenc, Faruk ^a   Yazicioglu, Ahmet ^a  

^a TURKIYE YUKSEK IHTISAS HOSPITAL   (Turkey)

Author keywords

CD44s; Renal cell carcinomas; Thrombus

Indexed keywords

HERMES ANTIGEN;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER INVASION; CANCER STAGING; CAVA VEIN DISEASE; CAVA VEIN THROMBOSIS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GLYCOSYLATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; KIDNEY VEIN THROMBOSIS; MALE; PRIORITY JOURNAL; PROGNOSIS; RNA SPLICING; THROMBOGENESIS; TUMOR GROWTH; TUMOR VOLUME;

AGED; ANTIGENS, CD44; CARCINOMA, RENAL CELL; CELL ADHESION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; RENAL VEINS; THROMBOSIS; TREATMENT OUTCOME; VENA CAVA, INFERIOR; VENOUS THROMBOSIS;

EID: 57649114773     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000167846     Document Type: Article

References (28)

1. Koukoulis GK, Patriarca CP, Gould VE: Adhesion molecules and tumor metastasis. Hum Pathol 1998;29:889-892.
2. Meyer T, Hart IR: Mechanisms of tumor metastasis. Eur J Cancer 1998;34:214-221.
3. Petruzzelli L, Takami M, Humes DH: Structure and function of cell adhesion molecules. Am J Med 1999;106:467-476.
4. Gilcrease MZ, Guzman-Paz M, Niehans G, Cherwitz D, McCarthy JB, Albores-Saavedra J: Correlation of CD44s expression in renal clear cell carcinomas with subsequent tumor progression or recurrence. Cancer 1999;86:2320-2326.
5. Borland G, Ross JA, Guy K: Forms and functions of CD44. Immunology 1998;93:139-148.
6. Fox SB, Fawcett J, Jackson DG, Collins I, Gatter KC, Harris AL, Gearing A, Simmons DL: Normal human tissues, in addition to some tumors, express multiple different CD44 isoforms. Cancer Res 1994;54:4539-4546.
7. Cooper DL, Dougherty GJ: To metastasize or not? Selection of CD44 splice sites. Nat Med 1995;1:635-637.
8. Terpe HJ, Störckel S, Zimmer U, Anquez V, Fischer C, Pantel K, Gunthert U: Expression of CD44 isoforms in renal cell tumors. Am J Pathol 1996;148:453-463.
9. Gilcrease MZ, Truong L, Brown RW: Correlation of very late activation integrin and CD44 expression with extrarenal invasion and metastasis of renal cell carcinomas. Hum Pathol 1996;27:1355-1360.
10. Fischer C, Georg C, Kraus S, Terpe HJ, Luedecke G, Weidner W: CD44s, E-cadherin and PCNA as markers for progression in renal cell carcinoma. Anticancer Res 1999;19:1513-1517.
11. Paradis V, Ferlicot S, Ghannam E, Zeimoura L, Blanchet P, Eschwege P, Jardin A, Benoit G, Bedossa P: CD44 is an independent prognostic factor in conventional renal cell carcinomas. J Urol 1999;161:1984-1987.
12. Hara I, Miyake H, Yamanaka K, Hara S, Arakawa S, Kamidono S: Expression of CD44 adhesion molecules in nonpapillary renal cell carcinoma and normal kidneys. Urology 1999;54:562-566.
13. Daniel L, Lechevallier E, Giorgi R, Lindner V, Framont M, Vieillefond A, Coulange C, Figarella-Branger D: CD44s and CD44v6 expression in localized T1-T2 conventional renal cell carcinomas. J Pathol 2001;193:345-349.
14. Sobin LH, Wittekind CH (eds): TNM Classification of Malignant Tumors, ed 5. New York, Wiley, 1997.
15. Fuhrman SA, Lasky lC, Limas C: Prognostic significance of morphologic parameters in renal cell carcinomas. Am Surg Pathol 1982;6:655-663.
16. Kearney GP, Waters WB, Klein LA, Richie JP, Gittes RF: Results of inferior vena cava resection for renal cell carcinoma. J Urol 1981;125:769-773.
17. Naor D, Sionov RV, Ish-Shalom D: CD44: Structure, function, and association with the malignant process. Adv Cancer Res 1997;71:241-319.
18. Aruffo A, Stamenkovic I, Melnick M, Underhill CB, Seed B: CD44 is the principal cell surface receptor for hyaluronate. Cell 1990;61:1303-1313.
19. Weber GF, Ashkar S, Glimcher MJ, Cantor H: Receptor-ligand interaction between CD44 and osteopontin (Eta-1). Science 1996;271:509-512.
20. Carter WG, Wayner EA: Characterization of the class III collagen receptor, a phosphorylated, transmembrane glycoprotein expressed in nucleated human cells. J Biol Chem 1988;263:4193-4201.
21. Gallatin WM, Wayner EA, Hoffman PA, St John T, Butcher EC, Carter WG: Structural homology between lymphocyte receptors for high endothelium and class III extracellular matrix receptor. Proc Natl Acad Sci USA 1989;86:4654-4658.
22. Kaufmann M, Heider KH, Sinn HP, von Minckwitz G, Ponta H, Herrlich P: CD44 variant exon epitopes in primary breast cancer and length of survival. Lancet 1995;345:615-619.
23. Wielenga VJM, Heider KH, Offerhaus GJA, Adolf GR, et al: Expression of CD44 variant proteins in human colorectal cancer is related to tumor progression. Cancer Res 1993;53:4754-4756.
24. Dall P, Heider KH, Sinn HP, et al: Comparison of immunohistochemistry and RT-PCR for detection of CD44v-expression, a new prognostic factor in human breast cancer. Int J Cancer 1995;60:471-477.
25. Fernandez-Figueras MT, Ariza A, Calatrava A, et al: CD44 and melanocytic tumors: a possible role for standard CD44 in the epidermotropic spread of melanoma. J Cutan Pathol 1996;23:133-139.
26. Salmi M, Gron-Virta K, Sointu P, et al: Regulated expression of exon v6-containing isoforms of CD44 in man: down-regulation during malignant transformation of tumors of squamocellular origin. J Cell Biol 1993;122:431-442.
27. Lucin K, Matusan K, Dordevic G, Stipic D: Prognostic significance of CD44 molecule in renal cell carcinoma. Croat Med J 2004;45:703-708.
28. Russo P, Snyder ME, Di Blasio CJ, et al: Changing demographics and the contemporary surgical management of renal cortical tumors. J Urol 2003;169:347A.